COMP <GO>
BGLC vs LLY // EV/EBITDA & P/E VALUATION
BioNexus Gene Lab Corp (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BGLC 0
— LLY 10
■ METRIC PARITY
LAST: $0.98 (-7.79%) • MKT CAP: $2.9M
valuation
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BGLC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BGLC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.60% | 83.64% | -69.04 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -39.90% | 40.21% | -80.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | -40.20% | 31.90% | -72.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -21.90% | 45.51% | -67.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.12 | 9.29 | -7.17 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 9/9 | -7.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.5 | 66.6 | -42.11 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.9M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BGLC REV | LLY REV | BGLC GROSS % | LLY GROSS % | BGLC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.4M | $65.18B | 14.6% | 83.0% | -$1.9M | $16.81B |
| FY 2024 | $9.5M | $45.04B | 13.6% | 81.3% | -$2.3M | $8.82B |
| FY 2023 | $9.8M | $34.12B | — | 79.3% | -$1.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BGLC // BETA —
LLY // BETA 0.51